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Abstract 
 
 
Ariful Islam 
MEDICATIONS DEVELOPMENT FOR DRUG ADDICTION AND OTHER 
NEUROPSYCHIATRIC DISORDERS 
2018-2019 
Thomas M. Keck, Ph.D. 
Master of Science in Pharmaceutical Science 
 
Drug addiction and abuse especially opiate and psychostimulant abuse is a national and 
global crisis. IBNtxA (3-iodobenzoyl naltrexamine) is a novel μ opioid receptor (MOR) 
agonist, a naloxone derivative, structurally related to the classical MOR antagonist 
naltrexone. Recent studies suggest IBNtxA preferentially signals through truncated MOR 
splice variants, producing a unique pharmacological profile resulting in potent analgesia 
with reduced side effects. It has been found that M. vaccae has immunoregulatory effects 
that can prevent stress-induced exaggeration of neuroinflammation in the brain. The 
purpose of our pilot study is to develop medication for addiction and neuropsychiatric 
disorders. According to our purpose, we evaluated a range of IBNtxA doses to more fully 
assess its abuse liability and antiaddiction properties and the preimmunization effect of 
heat-killed M. vaccae on cocaine addiction. IBNtxA represents an intriguing lead 
compound for preclinical drug development specifically targeting MOR splice variants, 
potentially creating effective analgesics with reduced side effects. Furthermore, IBNtxA 
could have use as an adjunct therapy in agonist replacement strategies (e.g., methadone). 
M. vaccae might be helpful for cocaine relapse. Current collaborative efforts are aimed to 
find the total signaling pathways of IBNtxA and the effect of M. vaccae on cocaine self-
administration, cocaine induced neuroinflammations and to keep finding medicine for 
neurological diseases.  
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Chapter 1 
Introduction  
Background 
 
A brief history of opiate drugs. Opiates are a very old class of analgesic drugs 
derived directly from the opium poppy. (Manglik et al., 2012)The term opiate refers 
specifically to [list compounds]. Since opium has a long history, it is pretty difficult to 
claim when it was first used (or abused), but scholars agree that the Sumerians in 
Mesopotamia, present-day Iraq, cultivated and isolated opium from the opium poppy 
(Papaver somniferu) around 3400 B.C. They named the plant “hul gil,” meaning “the plant 
of joy.”(Brownstein, 1993; Rosenblum, Marsch, Joseph, & Portenoy, 2008) In 1806, the 
German chemist Friedrich Wilhelm Adam Sertürner isolated morphine from opium and 
named it “morphine” after the god of dreams, Morpheus. (Brownstein, 1993; Duarte, 2005) 
In the 1850s, Alexander Wood reported that he had injected morphine into his wife as an 
experiment, using his invented syringe with hollow needle, and his wife died from 
respiratory depression. (Jonkman et al., 2018) 
In the United States, opiates like morphine have been used since the American Civil 
War as potent analgesics. Opiate use outside of medical treatment led to opiate abuse and 
addiction. The Harrison Narcotics Tax Act was passed in 1914 to curb the addiction and 
abuse of some highly addictive opiates and cocaine, which means possession without a 
prescription of these drugs inside the United States is a criminal offense. (Terry, 1915)  
The term opioid means opiate-like—a combination of the word opium and the 
suffix –oid, meaning “like” or “resembling”—originated in 1950, and was first proposed 
by Dr. George H. Acheson. (Wikler, Martin, Pescor, & Eades, 1963) Opioid drugs have 
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structural similarities with morphine but are either synthetic or semisynthetic. (Martin, 
1983) The endogenous (i.e., naturally occurring) opioid peptides, endorphins, were first 
discovered in 1974 by two independent group of investigators—John  Hughes and Hans 
Kosterlitz of Scotland, and Rabi Simantov and Solomon H. Snyder of the United States. 
(McLaughlin & Zagon, 2013) 
Opioid drug classifications. Opioid drugs encompass a broad spectrum of activity. 
According to their synthetic process, clinical opioids can be classified into three groups: 
1. Naturally obtained, extracted directly from poppy seeds, such as morphine, 
papaverine, and codeine; 
2. Semi-synthetic compounds, which feature modifications of natural compounds, 
including morphine esters such as heroin, oxycodone, and oxymorphone; 
3. Fully synthetic compounds, such as pethidine, fentanyl, and tramadol. (Jamison 
& Mao, 2015; Pathan & Williams, 2012) 
Opioids can also be classified based upon their binding affinity and effects on the four 
major opioid receptors: 
1. The δ-opioid receptor (DOR); 
2. The κ-opioid receptor (KOR); 
3. The μ-opioid receptor (MOR); 
4. The nociception/orphanin opioid receptor (NOR). 
Finally, opioids can be classified based on their signaling properties: 
1. Full agonists (e.g., morphine, etorphine, methadone, meperidine, codeine, 
hydromorphone etc.), which will fully activate a given opioid receptor; 
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2. Partial agonists (e.g., buprenorphine, pentazocine, nalbuphine), which will 
partially activate a given opioid receptor; 
3. Antagonists (e.g., naloxone, naltrexone insert other examples?), which will 
block the activity of agonists or partial agonists. (Jamison & Mao, 2015; 
Waldhoer, Bartlett, & Whistler, 2004) 
Other than clinical opioids, the body itself also produces opioid peptides, 
commonly known as endogenous opioids or endogenous ligands. These endogenous 
opioids bind to opioid receptors and exert pharmacological actions. (Holden; Li et al., 
2012; Waldhoer et al., 2004) Though there are many identified endogenous opioid 
peptides, they can be classified into three groups of ligands—enkephalins, endorphins, and 
dynorphins—which generally signal through the three major receptors, DOR, MOR, and 
KOR, respectively. (Li et al., 2012) 
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Table 1 
Common clinical and endogenous opioid ligands. (Egan, 2005; Endoh, Matsuura, 
Tanaka, & Nagase, 1992; Gilman, 2011; Jamison & Mao, 2015; Maisonneuve, Archer, & 
Glick, 1994; Pathan & Williams, 2012; Trescot, Datta, Lee, & Hansen, 2008) 
Opioid Ligands 
Mu Opioid 
Receptor 
Delta Opioid 
Receptor 
Kappa Opioid 
Receptor 
Nociceptin 
Receptor 
Endogenous Ligands 
β-endorphin +++ +++   
Enkephalins ++ +++   
Dynorphin A&B ++ + +++ + 
Nociceptin/orphanin 
FQ 
   +++ 
 Clinical and Nonclinical Ligands 
Agonists 
Morphine +++  +  
Codeine + + +  
Fentanyl +++ +   
Pethidine +++ + +  
Methadone +++    
U50,488   +++  
TAN-67 (SB-
205,607) 
 +++   
Partial Agonists 
Buprenorphine +  - -  
Pentazocine - + ++  
Antagonists 
Naloxone - - - - - -  
Naltrexone - - - - - - -  
Nor-
binaltorphimine 
  - - -  
 (+) sign indicates receptor selectivity of opioid agonists, more (+) sign means more selectivity, no (+) sign 
indicates, no selectivity. (–) sign indicates receptor selectivity of opioid antagonists, more (-) sign indicates 
more antagonist effect.  
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Opioid receptors. Opioid ligands signal through opioid receptors, which are 
members of the 7-transmembrane G protein-coupled receptor (GPCR) superfamily. Opioid 
receptors are widely found in the central nervous system but also found in the peripheral 
nervous system. (Stein, 2016; Waldhoer et al., 2004) Though these receptors belong to the 
same class, their functions and cellular localizations are quite different. Most full agonists, 
such as morphine, endomorphins, fentanyl, and pethidine, primarily show pharmacological 
effects upon binding through MOR. (Stein, 2016; Trescot et al., 2008) It has three major 
subtypes of MOR, μ1, μ2, and μ3, located (Figure 2) in the brain—primarily in the cortex, 
thalamus, periaqueductal gray (PG) —and spinal cord substantia gelatinosa. MOR are also 
heavily expressed in the intestinal tract. (Mao, 1999; Stein, Schäfer, & Machelska, 2003) 
Individual MOR subtypes have different functions: μ1 is responsible for supraspinal 
analgesia, and physical dependence; μ2 is responsible for respiratory depression, euphoria, 
physical dependence, reduced gastrointestinal motility, and miosis; and μ3 may affect 
vasodilation. (Mao, 1999; Stein et al., 2003) 
Endogenous opioids, like endorphin and encephalin, have more receptor selectivity 
for DOR over clinical opioids which are most available pontine nuclei, amygdala and 
olfactory bulbs of CNS (Figure 2). It has two subtypes δ1 & δ2, though individual subtype’s 
function is not so obvious but DOR responsible for analgesia, euphoria, physical 
dependence, convulsant, and antidepressant effects. (Chung & Kieffer, 2013; Mao, 1999) 
In the brain, KOR mostly presents in hypothalamus, periaqueductal gray, and claustrum; 
in the spinal cord, KOR mostly presents in the substantia gelatinosa (Figure 2). KOR 
activation produces spinal analgesia, sedation, miosis, dysphoria, neuroprotection, and 
diuresis. KOR has three known subtypes, κ1, κ2, and κ3. (Lalanne, Ayranci, Kieffer, & Lutz, 
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2014; Stein et al., 2003) NOR is densely expressed (Figure 2) in cortex, ventral forebrain, 
hippocampus, hypothalamus, amygdala, and in the dorsal horn of spinal cord. (Donica, 
Awwad, Thakker, & Standifer, 2013; Koob, Arends, & Le Moal, 2014) Activation of NOR, 
produces some physiological pharmacological responses such as anxiety, food intake, 
learning, locomotor etc. (Donica et al., 2013)   
Mechanisms action of opioid agonists. Opioids bind to opioid receptors, producing 
a series of intracellular changes resulting in pharmacological effects. First, GTP binding at 
Gα subunit, guanosine triphosphate (GTP) exchanges to guanosine diphosphate (GDP) that 
triggers α-GTP complex to dissociate away from the βγ complex (Figure 1). (McDonald 
& Lambert, 2005; Pathan & Williams, 2012; Stein, 2016) Free α-GTP and βγ interact with 
the target protein and inhibit adenylate cyclase, which decreases cyclic adenosine 
monophosphate (cAMP) inside the cell (Figure 2).(McDonald & Lambert, 2005; Pathan & 
Williams, 2012) MOR, DOR, and KOR signaling can also moderate Ca2+ channels (Figure 
1) in both pre- and post-synapse reduces Ca2+ inside cell and impaired the neurons’ 
excitability. (Simons, 1988; Stein, 2016) These intercellular events cause hyperpolarization 
as well as hinder neuronal firing in key nociceptive circuits and eventually reduces pain. 
(McDonald & Lambert, 2005; Pathan & Williams, 2012; Simons, 1988; Stein, 2016) 
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Figure 1. from McDonald and Lambert (2005) Mechanism of actions opioid 
receptor ligands. Binding of an opioid agonist to a G protein-coupled opioid 
receptor induces the Gα protein to exchange its bound GDP for GTP, which causes 
Gα-GTP complex to dissociate away from the Gβγ complex, and all G proteins to 
dissociate from the receptor. (Pathan & Williams, 2012) Free Gα-GTP and Gβγ 
interact with target proteins. αi/o, the G protein associated with all opioid receptors, 
inhibits adenylate cyclase, reducing synthesis of cAMP. Gα and Gβγ also have 
complex interactions at various Ca2+ and K+ ion channels. In neurons, opioid 
receptor activation typically results in the suppression of neuronal firing. 
(McDonald & Lambert, 2005) 
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 Extensive use of opioid drugs. 
         Pain management. Over a hundred years, opioids have been used for treating both 
chronic and acute pain which is not only the national health issue but also an important 
global health issue. In the United States, more than 100 million people suffer from chronic 
pain and among them, 5-8 million use opioid drugs for long-term treatment. (Jamison & 
Mao, 2015; Kalso, Edwards, Moore, & McQuay, 2004) Opioid analgesics are very 
effective in both cancer and non-cancer pain too. Several clinical studies showed that 
intravenous infusion of opioid analgesic significantly reduces the neuropathic pain like 
central pain, postherpetic neuralgia, mixed neuropathic pain. (Kalso et al., 2004) Numerous 
studies had confirmed the significance of different doses of oral opioid analgesics on 
neuropathic, musculoskeletal and other non-cancer pain. (Kalso et al., 2004) The 
effectiveness of opioid drugs to manage cancer pain has already been confirmed by WHO. 
Severe pain in cancer patients is very challenging to manage and almost 75%  of them need 
to be treated with opioids analgesics. (Thapa, Rastogi, & Ahuja, 2011) Among all opioid 
drugs, morphine alone is sufficient for 85% of patients as single pharmacotherapy to treat 
severe cancer pain. In other cases, combination therapy with other analgesics or anti-
neoplastic drugs can be more effective. (Gilson, Ryan, Joranson, & Dahl, 2004) 
Sometimes, switching from one opioid drug (which already has receptor-resistance) to 
another opioid drug can be effective to get superior analgesic effect. (Thapa et al., 2011) 
Though success rate of opioid drugs is higher in cancer pain management but there are 
many barriers make it intricate. Unavailability of morphine, economic crises in developing 
countries, and improper pain assessment are some of the obstacles for pain management. 
(Thapa et al., 2011)   
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Acute pulmonary edema. Morphine has been used for a long time to treat 
pulmonary edema. Because of the failure of the left ventricle, the pulmonary circulation 
also increases due to elevated hydrostatic pressure which causes extra fluids accumulation 
into interstitium and alveoli of lungs. (Ellingsrud & Agewall, 2016) The aim of pulmonary 
edema treatment is to reduce hydrostatic pressure through lowering preload and afterload 
that can be achieved by vasodilation. (Mattu, Martinez, & Kelly, 2005) It has been thought, 
though not obvious, morphine has both anxiolytic and vasodilatory properties which can 
treat elevated pulmonary fluids by dilation.(Ellingsrud & Agewall, 2016) The European 
heart failure guideline considered intravenous infusion of morphine 4-8 mg as treatment as 
a treatment of pulmonary oedema guideline in 2012  through the American College of 
Cardiology Foundation/American Heart Association did not consider morphine for treating 
this disorder as a treatment guideline. (McMurray et al., 2012; Yancy et al., 2013) 
However, the American Heart Failure Society suggests if morphine needs to be 
administrated then should be incautious. ("Section 12: Evaluation and Management of 
Patients with Acute Decompensated Heart Failure," 2010)  
Diarrhea. Interestingly opioid drugs can treat irritable bowel syndrome with 
diarrhea (IBS-D). Since there are limited options available for managing IBS-D, so finding 
new treatment methods is crucial. Investigations on phase-3 clinical trials have found a 
substantial effect of eluxadoline, a new oral mu opioid receptor agonist but it has mixed 
opioids effect such as it also agonist KOR but antagonist of DOR, on IBS-D. (Lembo et 
al., 2016)  
Cough. Codeine has been used for decades as an antitussive opioid medication for 
cough treatment. Numerous recent studies question the efficacy of codeine in treatment of 
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cough. One study found that codeine did not have any significant effect on chronic 
obstructive pulmonary disease (COPD) when compared to placebo even though it is a 
standard antitussive agent. (Smith, Owen, Earis, & Woodcock, 2006) Codeine is 
ineffective as a cough suppressant when it is generated due to upper respiratory disorder or 
COPD, and it is not even effective for an acute cough in children. The U.S. Food and Drug 
Administration (FDA) recently warned that any cough medication containing opioids 
should not be used by patients less than 18 years old. However, still few studies claim, 
codeine is effective for a chronic cough in adults. (McCrory et al., 2013) 
Anesthesia. Opioid analgesics, especially narcotic opioids, have been widely using 
as anesthetic agents for various terms of anesthetic medications practice. Opiates 
analgesics are commonly used for major surgeries most specifically the surgical operation 
of any patient who has the cardiovascular disorder. (Bovill, Sebel, & Stanley, 1984) The 
principal reason for using opioids in patients with the cardiovascular disease during surgery 
is the absence of cardiac depression. (Hug, 1992) Though opioid medications have some 
side-effects in comparison with other anesthetic agents narcotic opioids even many cases 
better. (Bovill et al., 1984; Hug, 1992)  Proper knowledge of opioids pharmacology, dose-
response curves, and possible adverse effects can easily help to manage limitations of 
narcotic opioid analgesics as anesthesia. (Hug, 1992) 
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Adverse Effects of Opioids 
 
Opioids analgesics accompany with inevitable adverse effects including respiratory 
depression, sedation, euphoria, constipation, bradycardia etc. (Ballantyne  & Mao 2003; 
DeWire et al., 2013) Along with side effects, other adverse effects such as the addiction, 
abuse, dependency, tolerance, hyperalgesia, and withdrawals symptoms make opioids 
analgesic difficult to deal. (Fields & Margolis, 2015; Jamison & Mao, 2015; Volkow & 
McLellan, 2016) 
Tolerance. The term drug tolerance or medication tolerance can be simply defined 
as when the body doesn’t response or show same pharmacological actions as it shows 
initially with the same drug which means body requires higher dose over time to 
demonstrate the desired therapeutic effect.(Savage et al., 2003) When drug tolerance 
happens due to repeated opioids drugs exposure, the term could be renamed—opioid 
tolerance.(Chang, Chen, & Mao, 2007)  Scientists had been investigating the mechanism 
behind this opioid analgesic tolerance and found multiple mechanisms but the most 
convincing mechanisms are opioid receptor desensitization and internalization.(Pan, 2007) 
Desensitized receptors decrease their functions by limiting cellular signaling and internalization 
causes receptors reduction on the surface of the cell membrane and decreases receptors 
availability for opioids ligand bindings. (Allouche, Noble, & Marie, 2014; Pan, 2007) This 
signal transduction event takes place by two steps: the first step of desensitization occurs 
through GPCR phosphorylation by G protein-coupled receptor kinases (GRKs) which 
makes receptors ready for the second step—arresting bindings. (Pan, 2007) Once arresting 
binding happens, it eventuates uncoupling G protein signaling from GPCRs through 
blockage of G protein binding and other than only develops desensitization, it also 
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promotes internalization. (Krupnick, Goodman, Keen, & Benovic, 1997) Switching to 
another opioid analgesic or in combination with other analgesics as a part of pain therapy 
helps to bypass opioid tolerance but probably finding complete new opioid agonist could 
be more helpful. 
Hyperalgesia. Opioid-induced hyperalgesia (OIH) is the state of a paradoxical 
nociceptive sensitization response due to long-term opioids exposure. (Lee, Silverman, 
Hansen, Patel, & Manchikanti, 2011) When it is supposed to reduce pain after getting 
opioid analgesic therapy, but patients, instead, become more sensitive to painful stimuli in 
many cases. Researchers interpreted that OIH is the consequence of opioid tolerance and 
probably the first sign of hyperalgesia. (Chang et al., 2007) The molecular mechanism is 
not yet well-characterized. Though a number of mechanisms have been assumed the 
general surmise is the neoplastic modifications in both peripheral and central nervous may 
lead to hyperalgesia. (Lee et al., 2011) The sign of OIH can be identified if there is a lack 
of pharmacological efficacious responses during management of chronic pain with opioids 
administrations. (Hayhurst & Durieux, 2016) This unwelcome OIH expression might be 
managed by administration of low-dose ketamine, methadone, a combination of morphine 
and dextromethorphan in 1:1 ratio, COX-2 inhibitors and also considering some other 
treatment strategies. (Lee et al., 2011) 
Addiction, abuse, and dependence. Addiction is a chronic and relapsing brain 
disease where patients irresistibly seek drugs even though they know about the detrimental 
consequences. Anything which can produce the feelings of euphemism can lead to 
addiction and abuse, and this can be a drug, food, sex etc. (Savage et al., 2003) Most of the 
opioid agonists can produce a reward, and direct to addiction, abuse and creates drug 
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dependence. In general, dependence can be defined as the condition where the subject is 
not able to cut down or quit specific substance because of long-term use, despite trying 
harder and when it does happen with opioid drugs, called opioid dependence. (Jamison & 
Mao, 2015; Rosenblum et al., 2008) Both addiction and dependence happen over time to 
obtain a reward. Opioids addictive and dependent patients can do anything such as stealing 
money or drug, begging, robbing or intimidating anyone to administrate drugs.  
Opioid withdrawal. Drug withdrawal is a bunch of symptoms which become 
obvious because of discontinuing or significant reduction all on a sudden of any substance 
with or without medical values which have been administrating. Usually, the drugs which 
can produce rewards may cause withdrawal disorders which might stay for a week or more 
after an abrupt massive interfering of the last dose. Withdrawal symptoms can occur after 
developing drug dependence. (Savage et al., 2003)  Nausea, vomiting, muscle cramping, 
depression, anxiety, opiate cravings, agitation etc. are common withdrawal symptoms. 
(Hanks & Hoskin, 1987) This is a great challenge to overcome during opioids addiction 
and dependence treatment. 
Neurobiological Processes in Drug Reward 
Now the question is how a super opioid analgesic can create drug addiction, abuse, 
and dependence? To understand this neurobiological mechanism, we need to know the 
opioid receptor’s location (Figure 2) and functions, the binding affinity of clinical opioid 
ligands to their receptors which have already been discussed. From the previous discussion, 
activating MOR, DOR and KOR is not only produces analgesic effects but also generates 
rewards feelings in the brain. Along with these, we need to the neuroanatomy of the reward 
pathway of the brain. The pleasure feelings come by the release of dopamine (DA) into 
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midbrain. (Fields & Margolis, 2015)  Dopaminergic neurons are the principal source of 
DA which are numerously found in midbrain and 90% percent of these are located in 
ventral part of the mesencephalon. (Chinta & Andersen, 2005) There are four major 
dopamine pathways (Figure 3)  by which DA can travel to different areas of the brain and 
body and convey messages like pleasure and reward, locomotion, thinking, cognition etc. 
(Adinoff, 2004; Fields & Margolis, 2015)  
Mesolimbic Pathway: This pathway is involved in pleasure and reward functions. 
The dopamine enriched ventral tegmental area (VTA), initiates dopaminergic action 
potentials and sends the signals to another area of the brain, nucleus accumbens (NAc) 
(Figure 3). The release of dopamine in NAc primarily produces reward and pleasures. 
(Adinoff, 2004) Overstimulation of this pathway causes addiction, abuse, and dependence.  
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Mesocortical pathway—dopamine is synthesized in VTA (Figure 3)  transmits signals 
from the VTA to the prefrontal cortex (PFC) which is involved in memory, motivation 
and decision making( Figure 3). (Puig, Rose, Schmidt, & Freund, 2014) The dopamine 
  
 
Figure 2. (Benarroch, 2012)The schematic illustration of the locations of opioid 
receptors and opioid-synthesizing neurons. The dopaminergic neurons (Figure 3) and 
opioid receptors sahred some common locations of brain, specially, the VTA and 
NAc, that are reward producing area. Opioids agonists activate the mesolimbic 
dopamine pathway as their target receptors and dopamine neurons located same area. 
(Adinoff, 2004; Chinta & Andersen, 2005; Kosten & George, 2002) 
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secretion in this area might be helpful in cognition behavior but it may also elevate the 
dopamine level in NAc by the mesolimbic pathway which will drive to addiction. (Yadav 
et al., 2014) The inappropriate function of this pathway may generate schizophrenia, 
ADHD (Attention Deficit Hyperactivity Disorder), and psychosis. (Puig et al., 2014) 
Nigrostriatal pathway—dopamine sends signals from the substantia nigra to the 
basal ganglia which are associated with the movement (Figure 3). (Puig et al., 2014) 
Inadequate dopamine secretion in this pathway causes Parkinson’s disease (PD).  
The tuberoinfundibular pathway is the final dopamine pathway where dopamine is 
synthesized in the hypothalamus (Figure 3) and conveyed the signal in the pituitary which 
functions on regulating prolactin hormone secretion (Figure 3).  
Opioid receptors are also numerously found in ventral area tegmental and nucleus 
accumbens (Figure 2), where dopaminergic receptors are located densely. So other than 
only to reduce nociception, opioid analgesics also produce euphoria by activating 
dopamine pathway and elevating dopamine in the midbrain. (Volkow & McLellan, 2016) 
When the mesolimbic pathway is activated, that primarily calls upon euphoric feelings and 
continuous euphemism leads to drug addiction, abuse, and drug dependence.(Adinoff, 
2004; Chinta & Andersen, 2005) Therefore, the addiction and abuse of opioid drugs will 
be increased with the number of prescriptions for these medications. 
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Figure 3. (Wikipedia, 2015) The dopaminergic pathways.  Mesolimbic pathway 
responsible for  reward &  pleasure feeling which is the principal reason of drug 
addiction also;  Mesocortical pathway control cognition and  activity; Nigrostriatal 
pathway controls motor function and tuberoinfundibular pathway maintains 
prolactin secretion.(Benarroch, 2012; Wikipedia, 2015) 
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Addiction Statistics: Effects on Health and Economics 
Opioid prescriptions have been increasing day by day, corresponding with an 
increase in opioid abuse. (Kuehn, 2007a) According to the very recent Annual Surveillance 
Report of Drug-Related Risks and Outcomes United States, in 2016, nearly 62 million 
people either filled or refilled opioids medications at least once, which was 19.1 percent of 
patients. (National Center for Injury Prevention and Control (NCIPC), 2017) The same 
report also shows: during 2015, opioid drug overdose caused 33,091 deaths and among 
them, 15,281 persons died from prescription opioid drug overdose.(National Center for 
Injury Prevention and Control (NCIPC), 2017) 
The overall addiction scenario can be elucidated from results of the 2016 National 
Survey on Drug Use and Health. According to this report, approximately 28.6 million 
Americans aged 12 or more use illicit drug categories which include hallucinogens, 
inhalants, methamphetamine, and the misuse of prescription pain relievers, tranquilizers, 
stimulants, and sedatives.  Among drug abusers, 3.3 million are pain relief prescription 
misusers. Approximately, in 2016, 11.5 million people (aged 12 or more) misused 
prescription pain relievers wherein 97.4 percent are opioid misusers also 1.9 million 
misused cocaine. Drug-induced death has been also increasing nearly steadily with time. 
In 2014, drug-induced deaths totaled 33,671; in 2015, the total increased 6.9% to 36, 2622 
in 2015, and in 2016 it further increased by 5.7%. If we compare between 2006 and 2016, 
then the percent of death has been increased shockingly almost 46 percent. (Centers for 
Disease Control and Prevention, 2018) 
Aside from the health issue, this is an extensive economic burden too. In 2007, the 
United States had to expend more than $193 billion for illicit drug use, and surprisingly 
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only the prescription opioid abuse cost was approximately $55.7 billion. (Center, 2011; 
Kuehn, 2007b) The overall scenario became worse in 2013 compare to 2007—wherein the 
economic burden was estimated to be $78.5 billion, which included increased healthcare 
and criminal justice costs.(Florence, Zhou, Luo, & Xu, 2016)  
Drug Addiction and Treatment 
Detoxification of opioid drugs is the primary goal for the treatment of opioid 
addiction. The treatment is often possible either by behavioral therapy or pharmacotherapy 
or combination of both therapies.(Carroll & Onken, 2005) 
Behavioral therapy. Upon based on the previous era, the success of behavioral 
therapy is significantly beneficial for treating drug addiction and abuse. There are different 
types of behavioral therapies: Cognitive behavioral therapy, contingency management, 
community reinforcement approach, motivational enhancement therapy, family behavioral 
therapy, and other behavioral approaches have been proved as worthwhile for managing 
different types of addictions.(Carroll & Onken, 2005; NIDA, 2018) 
Cognitive-behavioral therapy. Relapse is a very common problem for any kind of 
treatment against. CBT which includes functional analysis and skill training can 
significantly help in the prevention of relapse. (Hendershot, Witkiewitz, George, & 
Marlatt, 2011) Patients can learn different techniques to discriminate correct and incorrect 
behaviors that help them approaching a problematic situation to abstain from drug abuse. 
(Steve, Wendy, & Vic, 2009)  Individuals can develop adaptive strategies in unfavorable 
social conditions through specific skills such as eliciting knowledge about positive and 
negative consequences results of drug abuse, self-control about drug craving, avoiding 
possible vulnerable situation etc. (Carroll & Onken, 2005; NIDA, 2018; Steve et al., 2009) 
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In some addiction such as cocaine addiction, CBT can be more effective along with 
pharmacotherapy. (Carroll et al., 2004) 
Contingency management (CM). This behavioral therapy is based on tangible 
rewards to encourage the abstinence from drug and the rewards can be either voucher-
based reinforcement or prize incentive. (NIDA, 2018) If the drug test such as urine or 
breath test confirms drug-negativity, the patient will receive a monetary voucher (voucher-
based reinforcement CM) or win cash instead of the voucher (prize incentives based CM), 
either way, allows the patient to exchange food, goods or any service to reinforce his/her 
drug-free life. (Budney, Higgins, Radonovich, & Novy, 2000) A considerable number of 
patients have abstained from opioids or cocaine patients through this CM service. (Petry et 
al., 2005; Prendergast, Podus, Finney, Greenwell, & Roll, 2006) Though initially, the 
community was concerned about increasing gambling because of prize incentives later it 
was confirmed that this service did not promote gambling. (Petry et al., 2006) 
Community reinforcement approach (CRA). This behavioral therapy is 24-week 
therapy where patients also are rewarded with vouchers for treating cocaine and alcohol 
addicted people. (NIDA, 2018) Computer-based CRA is effective for opioids and/or 
cocaine-dependent patients. (Higgins et al., 2003) This version train adolescents about 
solving the problem, adjustment, communication skills and encouragement to participate 
in recreational activities. (Brooks, Ryder, Carise, & Kirby, 2010) 
Other behavioral therapy with different strategies also become helpful with or 
without pharmacotherapy.  
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Pharmacotherapy. 
 Methadone. Methadone hydrochloride, a MOR agonist, is the first line of opioid 
pharmacotherapy which has been used since 1972 upon the approval by the Food and Drug 
Administration (FDA).(Institute of Medicine (US) Committee on Federal Regulation of 
Methadone Treatment; Rettig RA) Despite this is an opioid agonist but it does not generate 
pleasure feeling and the long-lasting pharmacological on the body, makes a drug of choice 
for treating opioid addiction and dependence. (Stotts, Dodrill, & Kosten, 2009) The 
elimination half-life of methadone is 24-36 hours which is optimal for a longer period of 
detoxification.  The optimal dosing range for most of the patients is 60-150 mg/daily but 
the starting dose range is 20-30 mg/daily which can be gradually increased by 5-10 mg to 
catch the standard range. (Institute of Medicine (US) Committee on Federal Regulation of 
Methadone Treatment; Rettig RA; Stotts et al., 2009) The daily single dose of methadone 
can suppress the opioid withdrawal symptoms. Special precautions must be considered for 
the patients with chronic renal diseases and pregnant women and there is a very chance to 
grow methadone dependence on the fetus. (Institute of Medicine (US) Committee on 
Federal Regulation of Methadone Treatment; Rettig RA) Methadone pharmacotherapy is 
more effective with the combination of other behavioral therapy.  
Buprenorphine. This synthetic opioid receptor partial agonist is another important 
medication for opioid dependence. Buprenorphine does not produce euphoria and can 
greatly reduce opioid withdrawal symptoms that can be safely prescribed by primary care 
physicians. (Kahan, Srivastava, Ordean, & Cirone, 2011) Two different sublingual tablet 
formulations—just buprenorphine and the combination of buprenorphine and naloxone are 
available which was first approved by FDA in 2002. (NIDA, 2018; Stotts et al., 2009) The 
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maximum recommended dose of buprenorphine is 24 or 36 mg.  To reduce possible abuse 
liability, buprenorphine and naloxone ration 4:1 often choose over only buprenorphine. 
(Mendelson et al., 1999) Commercially buprenorphine to naloxone 2:0.5 or 8:2 
combination are available by the brand name Suboxone. (Kahan et al., 2011) One of a 
clinical trial showed that the ratio buprenorphine: naloxone, 8:2 and 32:8 mg is better than 
2:0.5 mg in reducing heroin replacement therapy. (Mattick, Kimber, Breen, & Davoli, 
2008) The treatment becomes more effective when behavioral therapy like extended 
weekly counseling is added with Suboxone administration. (Fiellin et al., 2006)  
National Institute of Drug Abuse (NIDA) clearly explained, as methadone and 
buprenorphine both are opioid drugs, so the treatment with both of these is more likely as 
a substitution of one addictive drug to another but in less addictively.  
Naltrexone. is an opioid antagonist which is synthetically obtained, can prevent 
opioid agonists to bind with their target receptors. (Stotts et al., 2009) It produces neither 
rewards nor considerable abuse or addiction which gradually detoxify opioids effects on 
the body. Once daily (must be taken with food) 50 mg tablet is a very common treatment 
though it can be extended to 100-150 mg in every two-three days—based on physician's 
judgment. (Krupitsky, Zvartau, & Woody, 2010; Stotts et al., 2009) Scientists have been 
trying to develop sustained release formulation, though some sustained release 
formulations were prepared, FDA denied the approvals. (Krupitsky et al., 2010; Stotts et 
al., 2009) It has been thought that the long-acting release of naltrexone can improve the 
treatment therapy. 
All of these treatment options with methadone or buprenorphine detoxify slowly. 
The drug-like clonidine, an alpha 2 adrenergic agonist, often as a combination therapy with 
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opioid antagonist naltrexone, can undergo rapid opiate detoxifications. (Gowing, Ali, & 
White, 2000) Even though this treatment option sounds wonderful but the obtained data 
from different studies could not ensure the claimed efficacy for opioid addiction treatment. 
(Stotts et al., 2009) 
Creating New Opioids 
“Prevention is better than treatment”—this is an apothegm; A new opioid analgesic 
without or limited abuse liability and with a lower side-effect will be an ideal treatment 
option for managing pain. Unfortunately, the opioid choice is limited. It was always being 
demanding to create a new opioid analgesic with less adverse effect.  
The first single opioid compound, morphine, was isolated from the tarry poppy seed juice 
by pharmacist Friedrich Wilhelm Adam Serturner in 1805. (Krishnamurti & Rao, 2016)  
After 120 years long research of isolation, morphine’s structure was established in 1925 by 
Sir Robert Robinson and it took around 30 years to find out the laboratory total synthesis 
of morphine which was developed by Marshall D. Gates.(Bentley, 1987; Gates & Tschudi, 
1956) Structural modification in some important positions by analyzing structure-activity 
relationships (SARs) in 4,5a-epoxymorphinan skeleton (Figure 3), in previous years, 
remarkably helped to create new opioids. (S. Majumdar et al., 2012; Pasternak & Pan, 
2013) 
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Figure 4. 4,5α-epoxymorphinan template (left) and morphine (right). The SARs of 
morphinan compounds have been primarily created by altering substituents at the three R 
groups. (Pasternak & Pan, 2013) 
 
 
Table 2 
 Examples of Some 4,5α-epoxymorphinan Compound’s  SARs Modification at Different 
Carbon. (Pasternak & Pan, 2013)  
Compounds  R1 R2 R3 
Morphine H CH3 H 
Codeine CH3 CH3 H 
Morphine-6-sulfate H CH3 SO3 
Morphine-6β-
glucuronide 
H CH3 Glucuronide 
Heroin 
 
Acetyl 
CH3 
 
Acetyl 
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 Structural features. The 4,5α-epoxymorphinan compounds (Table 2) have some 
common structural features: a benzene ring (A), cyclohexane rings (B and C) which are 
partially unsaturated, a piperidine ring (D) and with a dihydrofuran ring (E). A hydroxyl 
group especially at the C-3 position (Figure 4), play a vital role for narcotic analgesic 
effects, loss of free hydroxyl group significantly reduce the affinity of an opioid to MOR 
or it may produce some other effects such anti-tussive effect of codeine. (Pert, Pasternak, 
& Snyder, 1973)  Change at C-6 (Figure 4) with the different group also can affect the 
overall pharmacological properties—such as when hydroxyl groups of morphine are 
replaced by acetyl at both C-3 and C-6 positions, it elevates the lipophilicity and enhances 
blood-brain barrier (BBB) permeability.(DeRuiter, Fall 2000; Pasternak & Pan, 2013) The 
reduction of the double bond at C7-C8 (Figure 4) yields dihydromorphine, further 
substitution at C-14 by a hydroxyl group and oxidation of hydroxyl group at C-6 produces 
oxymorphone with more activity. A basic, tertiary amine at position 17 (Figure 4) plays an 
important role too, substitution of oxymorphone’s N-methyl group with an allyl group, 
makes an opioid antagonist, naloxone, and if replacement happens by an ethylcyclopropane 
it yields another opioid antagonist, naltrexone. A number of other modifications also have 
developed several different clinical opiates, including both antagonists and agonists (Table 
2). 
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Chapter 2 
A Novel Atypical Mu Opioid Receptor Agonist 3-Iodobenzoylnaltrexamide 
(IBNtxA) 
Scientists have been aspiring to generate novel opioid compounds with better 
analgesia but limited side-effects. Recently when a group of scientists from Memorial 
Sloan-Kettering Cancer Center, New York, had been synthesizing radiolabeled derivatives 
of the opiates, they found an atypical novel opiate, named- IBNtxA with wonderful 
pharmacological characteristics. (Susruta Majumdar, Burgman, et al., 2011; Susruta 
Majumdar, Grinnell, et al., 2011; S. Majumdar et al., 2012) This molecule was synthesized 
as a 6β-naltrexamine derivative which is an analog of naltrexone. When they substituted 
R3 position with 3-iodobenzene, R1 with methylcyclopropane and R2 with hydrogen, they 
found – IBNtxA (Figure 5).(S. Majumdar et al., 2012) Their investigation found—IBNtxA 
is potent than morphine when they tested analgesic properties by tail flick method, with 
lowered side-effects such as no respiratory effects, no physical dependence, and no place 
preference when they tested single dose.(Susruta Majumdar, Grinnell, et al., 2011)  IBNtxA 
possibly signals through truncated MOR splice variants—exon 11-associated 6 
transmembrane region splice variants (6TM/E11) but the role of  6TM/E11 is not well-
established though it’s been hypothesized that it can affect the analgesic signaling of some 
MOR agonists. (Lu et al., 2015; Susruta Majumdar, Grinnell, et al., 2011) 
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4,5-epoxymorphinan skeleton  
 
          
                         Naltrexone                                      IBNtxA 
 
Figure 5. SARs of  4,5-epoxymorphinan skeleton wherein the replacement of 
R1 at N-17 position by methyl cyclopropane, R2 at C-3 position by hydrogen 
and double bond with oxygen at C-6 position, produces opioid antagonist, 
naltrexone. Change in 4,5-epoxymorphinan skeleton at R1 and R2 same as 
naltrexone but replacement of R3 by 3-idobenzene creates an atypical mu 
opioid receptor agonist IBNtxA which is a derivative of 6β-naltrexamine with 
higher analgesic effects but limited side effects than morphine and highly 
selective to 6TM/E11 MOR splice variant.(S. Majumdar et al., 2012)  
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Recent molecular dynamics simulations studies (led by Dr. Chun Wu) on morphine 
and IBNtxA with 7-transmembrane (7TM)  and 6-transmembrane  (6TM)  of MOR splice 
variants, has confirmed that morphine is incapable to activate 6TM  where IBNtxA can 
activate but the interaction between IBNtxA and 6TM/E11 and 7TM splice variants 
remains unclear.(Sader, Anant, & Wu, 2018) This analysis also confirmed that IBNtxA has 
stronger binding properties to 7TM than morphine.(Sader et al., 2018)  The loss of exon 
11-associated MOR splice variants in knock-out (KO) mice, caused loss of analgesia for 
IBNtxA but the analgesic effect of morphine was unchanged and when exon 1-associated 
splice variants, DOR and KOR were knocked out, morphine was unresponsive to those 
animals but IBNtxA expressed, analgesia—both event indicates that IBNtxA may response 
through 6TM/E11. (Susruta Majumdar, Grinnell, et al., 2011) 
In this collaborative pilot projects we investigated: Analgesic properties of IBNtxA 
other than tail flick method, expanded abuse liability testing of IBNtxA using conditioned 
place preference (CPP),  potential anti-addictive impact of IBNtxA by measuring its effects 
on morphine CPP, whether IBNtxA affects morphine-induced locomotion, the subjective 
effects of IBNtxA (MOR/KOR/DOR signaling?) by drug discrimination techniques and 
provide a foundation for future studies dissecting the effects of IBNtxA on other receptors 
and evaluating analogues of IBNtxA.  
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Materials and Methods 
Animal. All experiments used male CD-1 mice or C57BL/6 mice obtained from 
Charles River Laboratories. All animals housed in the temperature- and humidity-
controlled Cooper Medical School of Rowan University vivarium, a barrier facility, under 
a 12 h light/dark cycle (lights on at 0700, off at 1900). Mice were group housed in 
polycarbonate cages with ad libitum food and water and enrichment provided by paper 
Bio-Huts and/or nestlets. Mice arrived at the facility approximately 28 days of age and 
were allowed to equilibrate to the facility for a minimum of seven days before beginning 
testing.  
CD-1 mice. CD-1 laboratory mice (Figure 6) are inexpensive and widely used in 
biomedical and pharmaceutical research. Most of the currently used mice are the progeny 
of nine Swiss mice, two male and seven female albino mice, which were imported to the 
USA in 1926 by Dr. Clara Lynch of the Rockefeller Institute for Medical Research, now 
named Rockefeller University.(Chia, Achilli, Festing, & Fisher, 2005) In 1948, new 
Ha/ICR mice were initiated from previously imported Rockefeller “Swiss” mice at the 
Institute for Cancer Research (ICR) in Philadelphia.(Chia et al., 2005)  
Characteristics of ICR (CD-1®) Mice: CD-1 (Figure 6) mice are white in color; 
usually they are docile and these mice grow with time which became maximum after fifteen 
weeks though the growth rate and weight gain are higher in male than female.(River, 2018) 
We started experiments when animals were around 35 days old, at that point we 
found the average weight of mice—approximately 34-36 gm. When we were working with 
CD-1 mice, in our observation, they were usually easy to handle but very first week they 
were outrageous, especially during drug administration. The reason behind their aggressive 
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behavior during the first few days—the time need for adaptation to human and drug 
administration.  
C57BL/6 mice. This is a typical inbred strain, most widely genetically modified 
laboratory mice for biomedical, pharmaceutical, translational science or any animal study 
research due to their availability and robustness. This strain was first developed by C.C. 
Little in 1921 which was eventually handed over to Charles River in 1974 from NIH. (Chia 
et al., 2005; River, 2018; Sarna et al., 2000) 
They are deep brown or almost black (Figure 7), highly sensitive to noise and 
odors; not docile like CD-1 mice and more likely to bite. They are barbering in nature, and 
dominant mice can remove hair and whisker of housemates. (Sarna et al., 2000) (Willott, 
Erway, Archer, & Harrison, 1995) Notwithstanding most of the different strains, these mice 
are highly susceptible to addiction, atherosclerosis and age-related hearing loss. (Willott et 
al., 1995) Like CD-1 mice, this strain also grows with time, reaching full weight after 
fifteen weeks; we started to weigh them after five weeks, and the average approximate 
weight was 18-22 g.  
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Figure 6:(Taconic Biosciences, 2018) Image of CD-1 outbred mouse, white in color 
and usually docile in behavior. These mice have been widely used in biomedical 
research. They are normal wild type mice, grow over time and gains maximum weight 
in fifteen weeks. (River, 2018)  
 
Figure 4: (LABORATORY, 2018) Stock photo of C57 mouse, genetically designed 
animal. This strain is deep brown or almost black, noise and odors sensitive; are highly 
susceptible to addiction, atherosclerosis and age-related hearing loss. They are barbering 
in nature, prone to engage fighting with inmates, resulting hair removal and sometimes 
possible injuries. (River, 2018; Sarna, Dyck, & Whishaw, 2000; Zurita et al., 2011) 
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Drugs. IBNtxA was synthesized at Rowan University by the laboratory of Dr. 
Gustavo Moura-Letts, who developed a three-step synthesis starting from naltrexone 
purchased from Tocris. Morphine sulfate was purchased from Henry Schein. Cocaine HCl 
was purchased from Sigma. Naloxone was purchased from Tocris. The other substances 
that were used—naloxone, buprenorphine, methadone, U50,(488), TAN-67 (SB-205,607). 
All drugs were delivered via intraperitoneal (i.p.) injection at a volume of 10 
mL/kg. Drug dilutions were premixed to provide a given mg/kg dose when given an 
injection volume scaled to mouse body weight, measured prior to every test. For example, 
a 35 g mouse would receive a 1 mg/kg drug dose via the injection of a 0.35 mL volume of 
a 0.1 mg/mL drug solution. IBNtxA was delivered in a 10% DMSO vehicle, prepared via 
stepwise mixing with 1% 6M HCl, 10% dimethyl sulfoxide (DMSO), and 89% 
physiological saline. All other drugs were readily dissolved in physiological saline, or 10% 
DMSO vehicle. All the drugs were kept secure inside a locker with a regulated inventory 
procedure under the control Dr. Bradford Fischer, who holds controlled substances licenses 
from the State of New Jersey and the U.S. Drug Enforcement Agency. 
Conditioned Place Preference (CPP) 
 
            Apparatus. The conditioned place preference (CPP) paradigm is a standard 
preclinical behavioral analyzing model which has been widely used for the investigations 
of abuse and addictions for illicit drugs, food, sex, etc. (Prus, James, & Rosecrans, 2009)  
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Figure 8: Photo of new CPP apparatus from our research lab, where in white chamber and 
black chamber for drug or vehicle-paired side and gray chamber in the middle is the neutral 
zone. The locomotor activity of animals is tracked by infrared and then signal is sent to 
MED-PC software to analyze and present on the monitor.  
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For IBNtxA-related CPP studies, we used modular CPP chambers from Stoelting 
for use with Any-Maze software. These chambers featured: with two rectangular shapes 
compartments which are connected through one small central compartment (Figure 8). 
Rectangular shaped compartments are either circular grid or square grid flooring with the 
similar marked wall. For M. vaccae-related studies, we used dedicated CPP chambers from 
Med-Associates for use with MedPC software. These chambers featured: three 
compartments in a rectangular box-shaped chamber, characterized by the white and black 
wall for two adjacent chambers of the center chamber which has a gray color wall (Figure 
8).  The center compartment doesn’t have specific features, neither paired with drug nor 
with the vehicle, and two gates between two adjacent compartments connected with this 
compartment which allows animals to move freely.   
General procedure. Initial preference: Before starting the training, we took 
consideration whether animals have any initial preference to any chamber.  For instance, 
we named two different compartments, suppose, circular grid compartment and square grid 
compartment. Prior to conditioning, we calculated the ratio of time spent in an individual 
compartment. Usually, in the unbiased experimental procedure, the drug-paired, and 
vehicle paired compartments are assigned randomly regardless of initial preference score 
but in a biased CPP study, the compartment which is least preferred by subject is paired 
with the drug for that individual. (Huston, Silva, Topic, & Müller, 2013)  
Drug conditioning: during conditioning (Figure 10), which also can be defined as 
training or acquisition, animals are repeatedly and alternately exposed to either the 
investigative drug while confined to one compartment or vehicle while confined to the 
other compartment. (Huston et al., 2013) 
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After assigned drug side and vehicle side for the individual, the mouse was confined 
to drug-paired compartment after injecting with drug and, in alternate sessions, the same 
animal was confined to vehicle paired compartment after getting vehicle injections (Figure 
10). Before drug/vehicle administration individual animal’s health and behavioral 
parameters—food intakes, percent of weight gained or lost, any injury due to fighting with 
mates, any infection for any possible reason, quality of stool, hyper or hypo activity—were 
noted and scored. Any animal which with considerable behavioral or health issue like 
sickness was separated and excluded from further experiments. The animals with good 
physiological conditions where then inject and placed inside pre-cleaned and proper-set the 
CPP chamber. For the development of a place preference, animals were trained as long as 
10 days acquisition period(Figure 9). Every time before the animal was placed inside CPP 
chamber, all apparatus was cleaned with 70% IPA and the beds were washed with water 
then cleaned by 70% IPA to eradicate microorganisms and get rid of from any possible 
previous odors. 
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Figure 95: The schematic illustration of CPP test. The animals arrive in vivarium of Cooper 
Medical School of Rowan University (CMSRU) and have been kept for five days. After 
two days of daily handling to make them comfortable with researchers, they are being 
placed in CPP chambers for initial preference for two sessions then ten days (ten sessions) 
CPP training. After successfully completing training they have been tested for CPP 
expression and finally stress/drug-induced reinstatement test followed by CPP extinction.  
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Figure 10.  The general schematic presentation of CPP procedure. This figure was 
adapted from (Fernandes & Fulton, 2016). 
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The trained mice were tested to analyze place preference score through CPP 
expression trial, during this phase subjects did not receive any injection, and they were free 
to move any compartment of entire apparatus (Figure 10).  
After completing CPP acquisition and expression (Figure 9), the conditioned mice 
were repeatedly exposed to all CPP compartments freely in absence of drug or vehicle. 
Three days of continuous trials led animals to loss of place preference—known as CPP 
extinction(Figure 10). (Prus et al., 2009) 
CPP reinstatement (Figure 9 &10), followed by extinction, can be induced by either 
re-exposure to the drug which is also defined as drug-primed reinstatement or stress. Our 
pilot project had analyzed drug reinstatement study through both ways which were used as 
a model of relapse.  
Two methods are widely followed for behavioral studies to investigate stress-
induced reinstatement: forced swim and foot-shock; our studies were designed for forced 
swim stress-induced reinstatement. (Can et al., 2012; Yavin Shaham, Uri Shalev, Lin Lu, 
Harriet de Wit, & Jane Stewart, 2003) Mice were placed in an inescapable cylindrical tank 
which was 30 cm height x 20 cm diameters and constructed of transparent Plexiglas. The 
water level was marked on the tank which was more than 15 cm but less than 20 cm, and 
the water temperature was maintained 25 to 28 degrees Celsius. One mouse was kept for 
force swim in one cylinder for 5-6 minutes and then was dried and placed in CPP. The 
stresses mice were used to test the anti-stress, anti-anxiety as well as anti-addiction effects 
of drugs.   
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Statistical analysis. A preference score is calculated from the difference between 
the time spent in the drug-paired compartment before CPP training and the time spent in 
the drug-paired compartment on test day after CPP training—during CPP expression.  
𝑃𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑆𝑐𝑜𝑟𝑒 =  𝑡𝑖𝑚𝑒𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 − 𝑡𝑖𝑚𝑒𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑠𝑖𝑑𝑒   
Drug Discrimination 
Animal and drug. CD-1 male mice (Figure 6)were used for drug discrimination 
studies. Mice were food restricted for 6-12 hours prior to experiments but they have 
adequate access to water and air. Two group animal were used: one group was trained with 
morphine 3mg/kg and DMSO vehicle (1% 6M HCl, 10% DMSO and 89% saline), well-
trained animals were tested with novel drug (1-3 mg/kg IBNtxA and 0.1, 1, 3 and 10mg/kg 
morphine and another group received training with 3mg/kg IBNtxA and vehicle, and 
trained animals were tested with morphine (1-30 mg/kg), buprenorphine (0.1-3 mg/kg) a 
non-selective MOR/DOR/KOR agonist and fentanyl (0.01-0.3 mg/kg) a MOR-1 agonist,  
U50,488 a KOR-selective agonist, (1-20 mg/kg), a DOR-selective agonist, TAN-67 (SB-
205,607) morphine (1- 30 mg/kg), a MOR-1 agonist. 
Apparatus. Drug discrimination study was designed in the murine model, to 
understand whether the subjective effects of IBNtxA were similar to morphine. The DD 
apparatus has consisted of eight small boxes (Figure 11) which were designed by cutting 
edge technology. Each small box made of acrylic transparent glass which was covered by 
a spacious larger wooden box. All boxes were connected via different cables with 
computers where MED-PC software converted the animals’ behavioral activity to data and 
showed on the monitor. 
Each box had two nose poke holes: one for drug and another one for vehicle side 
(Figure 11). When animals nose poked on either side, an infrared beam was broken and a 
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signal was sent to the operating MED-PC software. During the experimental session, boxes 
were enclosed to isolate animals from other outside environmental factors, but during 
confinement, they received adequate air and light. A liquid dipper was located between the 
two nose poke holes, connected via tubing to a syringe (Figure 11) that discharged vanilla 
Ensure, a palatable food reward, for 3 seconds (delivering an approximate 0.1 mL volume) 
as a reward when animals earned a programmed reward. To earn the reward, animals were 
required to complete a specific pattern of correct responses: the required number of correct 
responses to earn a reward is known as the fixed ratio (FR). An FR10 training paradigm, 
for example, requires that the animal complete 10 correct nose pokes in a row to earn a 
reward. MED-PC software regulated the total system. 
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Figure 61. Schematic illustration of drug discrimination apparatus. The left hole is 
vehicle-paired; if animals knock this hole on vehicle-training session is considered as 
correct response and the right hole is drug-paired; on drug-training session if animals 
knock this hole, is considered as correct response. For every ten correct nose pokes, 
animals receive one single reward which is three seconds Ensure Plus syrup discharge 
through reward spout. During substitution test day any nose pokes to either side are 
considered for reward. The speaker on top of image is a sound generator which 
produces a tone during reward delivery.  
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Procedure. Animals were food restricted up to 24h before training or testing. 
During food restriction, animals have ad lib access to water. The weight of food-restricted 
animals was measured, and other visible health parameters were evaluated, including stool, 
appearances, and physical hyper/hypo-activities. After setting everything based on 
protocol, animals were injected and placed inside the boxes for training or test.  
In our FR schedule, the subject must complete a set number of correct responses 
during the training period to obtain one reward, and our research considered maximum ten 
correct responses as FR to get a single reward. Fixed ratio ten means if animals knock ten 
times to correct side they will get one reward. For elucidation, when a mouse received 
training drug, the correct responses were considered if that animal hit on drug side and 
there was no reward for the incorrect response that means vehicle side response.  The 
procedure was almost the same as the training session for substitute test except animals 
were free to choose any side for their rewards.   
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Figure 72. Outline of drug discrimination training. From the top of this image, after 
getting injection (i.p.) animals are placed inside DD box, and after 15 mins stimuli 
appears. Subject receives reward of three seconds liquid food dispense through reward 
spout for every ten correct responses. The training session becomes automatically end, 
either getting 50 rewards or after 60 mins or both.   
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Total procedure can be showed as this way (Figure 12): Injection ( i.p.) > stimuli 
present ( after 15 minutes ) > response to correct side (FR=10) > Reward ( 3 sec chocolate 
syrup discharge ) > end of single training session ( Either after 50 reward and/or 60 minutes 
) . (Solinas, Panlilio, Justinova, Yasar, & Goldberg, 2006) At the end of each day 
experiment, all apparatus was cleaned with animal sanitary napkins, 70% IPA and water.  
Two groups animals—each group contained eight CD-1 mice has been trained. One 
group was trained with vehicle (1% 6M HCl, 10% DMSO and 89% NaCl) and morphine 
3 mg/kg. To train mice properly and unbiasedly, the pattern of training was always being 
changed in each week for overcoming any possible effect of training schedule pattern 
which might affect discrimination study. 
The animals which could not reach the standard training with minimal 80% initial 
correct, 80% total correct response and 80% reward were excluded beforehand. 
Furthermore, every animal was kept in close observation for any health issue such as 
weight loss, stool condition, any possible injuries etc. Sick animals were separated from 
other mates and treated with required medicines. The animals with better health were 
trained and tested only.   
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Statistical analysis. Following equations were used for analysis: 
For training. 
% 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
= (
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝑇𝑜𝑡𝑎𝑙 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
) × 100 
 
% 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
= (
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑖𝑛𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
) × 100  
  For the substitution test. 
% 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
= (
𝑇𝑜𝑡𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 
𝑇𝑜𝑡𝑎𝑙  𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝑇𝑜𝑡𝑎𝑙 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 
) × 100 
% 𝑜𝑓 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒
= (
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑢𝑔 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠 + 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑠𝑖𝑑𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
) × 100 
 
For the rate of response. Other than only considering percent of the response to 
drug/vehicle side, the response rate is also a crucial factor for drug discrimination study. A 
consistent and proper response rate confirmed the appropriate training dose and the 
possible range of dose which might be tested for a drug. Furthermore, the rate of response 
helped to analyze some certain behavioral study of animals such as sedation, hyperactivity 
or hypoactivity etc. for DD study. ("Frontiers in Neuroscience," 2009) 
The simple equation is as follows: 
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑟𝑎𝑡𝑒 =
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑡𝑖𝑚𝑒
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Analgesic Test: Hot Plate Technique  
 
Animal and drug. Male CD-1 mice, 40-50 days old, obtained from Charles River, 
had free access to food and water, exposed to a light-dark cycle of 12 h were used for this 
test.  
Hot plate test was used to evaluate the analgesia of IBNtxA and then to compare 
with morphine. Novel drug IBNtxA 1 mg/kg and 3 mg/kg and morphine 10mg/kg were 
administrated by intraperitoneal (i.p.) injection. Three groups of animals, each containing 
eight animals, were assigned to receive 1 mg/kg IBNtxA, 3 mg/kg IBNtxA or 10 mg/kg 
morphine. 
Apparatus. The hot plate analgesia meter (Columbus Instruments, OH, U.S.A.) for 
small laboratory animals were used for this analgesic test. The hot plate could continuously 
provide 55°C temperature on an aluminum surface, with a digital built-in thermometer to 
maintain surface temperature to 0.1 °C precision and a timer with a 0.1 sec precision. The 
square shaped surface plate was enclosed by a clear acrylic cage to confine animals during 
testing. Pushes on start/stop button related to the timer, which displayed the time on the 
screen which was recorded manually. 
Procedure. The hot plate was set at 56 °C to observe the effects of drugs on animals. 
Certain behavioral changes, paw licking, flutter, and jumping, were considered as an 
animal’s pain feeling. (Rezaee-Asl, Sabour, Nikoui, Ostadhadi, & Bakhtiarian, 2014) 
Latency time after placing mice on the metallic hot plate provided the threshold level of 
animals. Prior to injecting the drug, each mouse was weighed and tested for two baseline 
studies where the animal was not injected with any drug or vehicle. After baseline studies, 
testing drug was administrated and animals were placed on hot plate in 15, 30, 45, 60, 
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and/or 75/90 minutes time intervals to collect the latency time. If any behavioral change 
like paw licking, flutter or jumping had been observed, the mouse was immediately 
removed from hot plate and latency time was recorded. Animals were removed from hot 
plate after 20 seconds even though there was no considerable behavioral change to avoid 
tissue damage and this specific time is known as maximum latency time. Any animal which 
showed more latency time more than 20 seconds was excluded from further investigation. 
(Menéndez, Lastra, Hidalgo, & Baamonde, 2002; Rezaee-Asl et al., 2014) 
Statistical Analysis. The anti-nociceptive effect for each dose was calculated as the 
% of the Maximal Possible Effect (% MPE) using the following formula: 
 % 𝑀𝑃𝐸 = (
𝐿𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑢𝑔 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑎𝑟𝑡𝑖𝑜𝑛−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠
{ 𝑀𝑎𝑥𝑖𝑚𝑎𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 (20)−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠}
) × 100 
Open-Field Locomotion Test 
 
Animal and drug. Male C57 mice were used and IBNtxA 3 mg/kg and and 
morphine 10mg/kg were administrated by intraperitoneal (i.p.) injection. There are two 
types of vehicles had been used: 1% 6M HCl, 10% dimethyl sulfoxide (DMSO), and 89% 
physiological saline (DMSO vehicle ) and only physiological saline (0.9 % NaCl). Three 
groups of animals, each containing eight animals, were assigned to receive 1 mg/kg 
IBNtxA, 3 mg/kg IBNtxA or 10 mg/kg morphine. 
Apparatus. The open-field locomotor test was determined by using 40*40*35 cm 
Plexiglas® open-field (Figure 13) and a camera mounted overhead, recorded and tracked 
locomotion of animals which was connected to the Any-maze behavioral analysis software 
of a computer. The field was divided by two regions: center region by 20*20 cm and rest 
of area for outer regions.  
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Figure 83. Schematic presentation of open-field box which is 404035 cm 
Plexiglas® with a camera on the top of box is connected through cable with computer 
operated Any-maze software which tracks and analyzes animal’s locomotor activity. 
The total open-field is separated into two zones—center zone (2020 cm) and outer 
zone. 
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Procedure. The procedure was simple—every animal was pre-weighed before 
treated with vehicle or drug then was placed inside the confined open-field for 40 mins to 
investigate the locomotor activity.  
To understand the effect of novel drug (IBNtxA) on morphine-induced locomotion, 
at first animals were injected with either IBNtxA or DMSO vehicle (1% 6 M HCl, 10% 
DMSO, 89% saline), were kept in home cages for 15 minutes then they were injected (i.p.) 
with morphine and were placed on field for 40 mins. The wall of boxes and beds were 
cleaned and dried every time for each animal’s testing with 70% IPA to avoid possible 
microorganism contamination as well as previous any kind of smell.  
Statistical Analysis. The total distance, time in the center zone, and time in outer 
zones were collected for further behavioral analysis. Total distance traveled by animals 
was statically analyzed using GraphPad Prism 6.0 statistical analysis software. 
Results 
Hot plate Analgesic Test: IBNtxA is more potent than morphine. According to 
the description above, the three group (n=8) of C-57 mice were injected intraperitoneally 
with two different strength of IBNtxA—1 mg/kg and morphine 10 mg/kg. When we 
compared the percent maximal possible effect (MPE) in the hotplate analgesic test of novel 
IBNtxA with classical MOR agonist analgesic morphine, we found that 3 mg/kg IBNtxA 
was more potent than 10 mg/kg morphine but 1 mg/kg IBNtxA did not show any 
considerable efficacy (Figure 14). Both IBNtxA 3mg/kg and morphine 10 mg/kg exhibited 
their maximum pharmacological action after 30 mins, wherein novel drug showed more 
than threefold more analgesia than control drug. In term of duration of action, the 
therapeutic curve indicated that morphine had a longer analgesic effect than IBNtxA. 
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Morphine took more than 90 mins to be reduced in zero percent MPE but IBNtxA took 60 
mins. The possible reasons behind the difference between the duration of action between 
two drugs—half-life, protein bindings, and metabolism. 
Conditioned Place Preference: IBNtxA does not induce a place preference 
Using the method described previously, nine groups of C57 mice (n=6-15 for each group) 
were tested for morphine- or IBNtxA mediated place preference. Animals were 
administered (i.p.) morphine, IBNtxA, or vehicle in a two-compartment CPP chamber. One 
group received normal biological saline, four groups received different doses (0.1, 0.3, 1 
and 3 mg/kg) of IBNtxA, another four groups of mice received four different doses (1, 3, 
10, and 20 mg/kg) of morphine. Animals were assigned for drugs or saline administration 
in an unbiased method. According to our research plan, we compared the preference score 
of among control (saline), well-known MOR analgesic (morphine) and the novel atypical 
MOR agonist (IBNtxA). IBNtxA did not show any statistically significant preference score 
compared to morphine (Figure 15). The morphine-induced place preference score of was 
initially increasing with the increase of dose which decreased later in higher dose: there 
was no preference for 1 mg/kg, little preference score but nonsignificant for 3 mg/kg and 
high preference score for 10 mg/kg which was more than 20 mg/kg morphine dose. The 
comparison of preference score between 3 mg/kg IBNtxA and 10 mg/kg morphine 
(analgesic test showed both are effective and equivalent) exhibited significant CPP score 
difference wherein IBNtxA did not exhibit preference but morphine had highest preference 
score (Figure 15). 
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Conditioned Place Preference: IBNtxA reduces morphine-induced CPP.  To 
investigate the effect of IBNtxA on morphine-induced CPP, three groups (n=10-11 each) 
of animals were used. Where all animals received morphine 10 mg/kg, but the pre-
treatment substances were different for the three groups. The pretreatment time was 15 
mins prior to inject (i.p.) morphine wherein first group was pre-injected with saline, the 
second group was pretreated with IBNtxA 1 mg/kg and the third group were pre-injected 
with IBNtxA 3 mg/kg. The result showed that mice those were pretreated with saline and 
IBNtxA, showed a preference for the drug side which indicated, IBNtxA 1mg/kg did not 
reduce the preference score (Figure 16). Animals which were pre-treated with IBNtxA 3 
mg/kg, did not show any significant preference score which indicated that IBNtxA 3mg/kg 
significantly reduced the morphine-induced conditioned place preference score (Figure 
16). 
Open-field locomotor test: IBNtxA attenuated morphine-induced 
hyperlocomotion 
Four groups (n= 6-11 per group) of C57 mice were used for this investigation. There were 
two stages of injection: pre-injection and post-injection—pre-injection were administrated 
15 mins prior to get post-injection.  Four groups of animals were assigned drug and vehicle 
according to the following ways—Group-A: pre-injection with IBNtxA 3 mg/kg and post-
injection with morphine 10 mg/kg, Group-B: pre-injection with DMSO vehicle and post-
injection with morphine 10 mg/kg, Group-C: pre-injection with IBNtxA and post-injection 
with saline and Group-D: pre-treatment with DMSO vehicle and post-injection with saline. 
The locomotor activity of Group-A, C and D were lower, but Group-B showed higher 
locomotor activity which clearly exhibited the morphine-induced hyperlocomotion (Figure 
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17). The animals which were pre-treated with IBNtxA 3 mg/kg prior to receiving morphine 
10 mg/kg, showed normal locomotor activity like Group-C and D wherein animals were 
treated with vehicle, saline or IBNtxA(Figure 17). Further data analysis among all groups 
indicated that IBNtxA reduced the hyperlocomotion activity induced by morphine 10 
mg/kg, moreover, IBNtxA did not have hyperlocomotion (Figure 17). 
Drug Discrimination Study: IBNtxA partially substitutes for morphine 
According to the method mentioned earlier, animals (n=8) were trained with morphine 3 
mg/kg were tested for drug substitution of IBNtxA. It took almost 60 days to train animals 
well and then in each week one single dose of the even for the same drug was tested.  When 
animals were well-trained (more than 80% correct response), they were tested with DMSO 
vehicle, morphine (0.3, 1, 3, 10 mg/kg) and IBNtxA (effective analgesic dose 3 mg/kg). 
The response to drug side was increased with the increase of a dose of morphine (Figure 
18). The animals when pre-injected with naloxone 1 mg/kg before injecting morphine 3 
mg/kg and asked to choose drug or vehicle side and they did not respond to the morphine 
side (Figure 18) which indicated that naloxone blocked the morphine to bind with target 
receptors. Finally, animals were tested for discriminating of IBNtxA with morphine and 
the result showed IBNtxA partially substituted morphine (Figure 18).  
The response rate is critical to evaluate alongside the substitution results. Drug 
doses that substantially suppress behavioral responding can complicate interpretation of 
substitution results. The average response rates during the last four days of training with 
both morphine and vehicle were very similar, but slower than the average response rates 
of vehicle and low doses of morhine during substitution tests. During the test with 
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morphine, the rate of response curve was fallen downward when the dose was increased 
from 1 mg/kg to 10 mg kg but lower dose morphine caused high response rate (Figure 19).  
Discussion 
IBNtxA has a powerful analgesic effect, comparable to morphine, which is very 
crucial for alleviating moderate to severe pain. The patients with severe pain—i.e., those 
with cancer or major surgery—need potent analgesic. IBNtxA was effective at a lower dose 
compared to morphine. Our hot plate study has confirmed that IBNtxA induced analgesia 
comparable to morphine at a dose that did not produce conditioned place preference 
(Figure 14). A drug with potent analgesic effect with no or minimum addiction is very 
important to reduce addiction, abuse, and dependence. Place preference score, in a rodent 
model, has been widely used to correlate with the addiction ability of a drug. Our 
investigation expanded the abuse liability studies of IBNtxA by using preference score 
induced different doses which were compared with different doses of morphine-induced 
place preference scores (Figure 15). Since IBNtxA did not produce any considerable place 
preference, it might not have an addiction or abuse liability.  
There are very few drugs such as buprenorphine, naltrexone and methadone are 
available for opioid replacement therapy or adjuvant therapy for opioid addiction. Our 
research has confirmed that IBNtxA significantly reduces the morphine-induced CPP 
(Figure 15) which is correlated with the anti-addiction potentiality of IBNtxA. Moreover, 
we found that it also suppressed the morphine-induced hyperlocomotion (Figure 17) that 
is also some sort of related to drug seeking behavior. Since IBNtxA suppresses both CPP 
and hyperlocomotion which are induced by morphine, so it might have potent anti-
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addiction properties which could be used as an opioid replacement therapy for opioid 
addiction pharmacotherapy.  
As a novel atypical MOR agonist, we have been investigating how IBNtxA 
signaling through, what are the  
subjective effects of this drug. The drug discrimination study which we have been 
conducting to find out these questions. The part of this study has already been completed, 
showed that IBNtxA partially substituted morphine (Figure 18). The previous studies 
conjected that it might be signaling through truncated E11/6TM splice variant of mu opioid 
receptor, but morphine does not signal through this splice variant, rather, it signals by full 
MOR. So, to know more about IBNtxA’s subjective effects, one group of animals is 
currently being trained to discriminate 3 mg/kg IBNtxA from DMSO vehicle. Once fully 
trained, they will be tested for drug substitution with morphine (1-30 mg/kg), 
buprenorphine (0.1-3 mg/kg), fentanyl (0.01-0.3 mg/kg), U50,488 (1-20 mg/kg), and TAN-
67 (SB-205,607, 1-20 mg/kg). All the substitute results will soon confirm the subjective 
effects of IBNtxA. 
Conclusions 
 The opioid epidemic is now a widely known term for America as well as other 
parts of the world. America has been fighting against this crisis for a longer time. Our 
collaborative research has confirmed that IBNtxA does not have possible addiction liability 
through our extended CPP test. Moreover, we also confirmed the possible anti-addiction 
ability of this drug along reconfirmed the stronger analgesic effect of IBNtxA. We are very 
close to finding out the subjective effect of this molecule which will be providing more 
obvious information for understanding IBNtxA signaling mechanism. A new clinical 
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opioid analgesic with higher potentiality but lower side-effect could be a groundbreaking 
medicine to fight against opioid addiction.  
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Figure 94. IBNtxA hot plate analgesia in CD-1 mice. Three groups of mice (n = 8 each) 
received 1 mg/kg IBNtxA, 3 mg/kg IBNtxA, or 10 mg/kg morphine i.p., and were tested 
independently on a 56° C hot plate. 30 min after injection (time = 0 min), 3 mg/kg IBNtxA 
and 10 mg/kg morphine showed peak analgesic effects. 1 mg/kg IBNtxA did not show an 
analgesic effect. From the dose-response above, it can be inferred that 3 mg/kg IBNtxA is 
comparable in analgesic potency to 10 mg/kg morphine. Results were evaluated as  
 
% 𝑀𝑃𝐸 = (
𝐿𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑢𝑔 𝑎𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑎𝑟𝑡𝑖𝑜𝑛−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠
{ 𝑀𝑎𝑥𝑖𝑚𝑎𝑙 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 (20)−𝑀𝑒𝑎𝑛 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 𝑡𝑖𝑚𝑒 𝑜𝑓 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑠𝑡𝑢𝑑𝑖𝑒𝑠}
) ×
100.   
All data are presented as means ± SEM. 
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Figure 105. CPP scores comparison among saline, morphine, and IBNtxA. One group 
(each group contains n=6-15) mice were treated with saline which did not have a preference 
score. Four groups animals received four different doses of IBNtxA and other four groups 
mice received four doses of morphine. The initial preference was for three sessions and 
then training for 10 sessions after that CPP expression for just single session and every 
session of each stage was for 30 mins. The result confirmed that IBNtxA (green color) did 
not have a preference when was compared with saline’s and morphine’s (red color ) 
preference score. The score was calculated by subtracting the pre-training preference score 
(drug-paired chamber) from the preference score (drug-paired chamber) of the post-
training test. Data are presented as means ± SEM. *p < 0.05, repeated-measures 2-way 
ANOVA with Sidak's multiple comparisons test. 
 
58 
 
 
Figure 116. The effect of IBNtxA on morphine-induced place preference.  Three groups 
of animals (n=10-11 per group) which were pretreated with DMSO vehicle, 1 mg/kg 
IBNtxA, or 3 mg/kg IBNtxA prior to every 10 mg/kg morphine administration during a 
10-day training regimen. After training, CPP expression was measured in a 30-minute 
session in which animals had free access to both drug- and vehicle-paired chambers. 1 
mg/kg IBNtxA did not reduce morphine-induced CPP, but mice pre-treated with 3 mg/kg 
IBNtxA prior to receiving 10 mg/kg morphine showed no morphine place preference. 
These results indicate that 3 mg/kg IBNtxA attenuated the morphine-induced CPP 
expression. The data are presenting with means ± SEM. *p < 0.05, repeated-measures 2-
way ANOVA with Sidak's multiple comparisons test. 
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Figure 12. Drugs and/or vehicle-induced locomotor activity. Four groups of animals (n= 
6-11 per group) which among two groups of them were pre-treated with 3 mg/kg IBNtxA 
before getting post-injection with 10 mg/kg morphine and another group with saline. Other 
two groups were pretreated with DMSO prior to receive morphine 10 mg/kg or saline. 
Among them animals, received IBNtxA and Morphine traveled significantly less distance 
than the animals which received DMSO vehicle before getting the same dose of morphine 
which indicated IBNtxA can suppress morphine-induced hyperlocomotion. Data are 
presented as means ± SEM. 
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Figure 18. Drug discrimination study with morphine-trained animals. CD-1 outbred mice 
(n=8) were trained for almost 60 sessions and the duration of each session was an hour and 
10±5 mins. The well-trained animals with more than 80% correct response, were tested for 
discrimination among vehicle, morphine (0.3, 1, 3, and 10 mg/kg) and novel drug IBNtxA 
3 mg/kg, the result showed that IBNtxA was a partial substitution of morphine. Pre-
treatment (i.p.) with naloxone 1 mg/kg prior to injecting morphine, showed that the 
morphine response is as lower as a percent of vehicle training responses to morphine side. 
This is obvious that antagonist naloxone blocked the morphine. The percent of morphine 
responding was calculated by taking the ratio of morphine responses over total responses. 
Data presented as means ± SEM. 
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Figure 1913: Rate effects of drug doses in the drug discrimination study with morphine-
trained animals. CD-1 outbred mice (n=8) were trained for almost 60 sessions and the 
duration of each session was an hour and 10±5 mins. The well-trained animals with more 
than 80% correct response, were tested for discrimination among vehicle, morphine (0.3, 
1, 3, and 10 mg/kg) and novel drug IBNtxA 3 mg/kg, the result showed that IBNtxA was 
a partial substitution of morphine. The rate of responding was calculated as: 
𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑟𝑎𝑡𝑒 =
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑡𝑖𝑚𝑒 (𝑚𝑎𝑥𝑖𝑚𝑢𝑚 60 𝑚𝑖𝑛𝑠)
 
Data presented as means ± SEM. 
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Chapter 3 
Mycobacterium vaccae Immunization for Drug Addiction, Relapse, and Withdrawal 
Background 
Addiction is a major health issue which brings upon other health complications with 
economic burdens. According to the 2016 National Survey on Drug Use and Health, around 
1.7 million people misused stimulant drugs in the U.S.A. and 2.2 percent of them are young 
adults.(Center, 2011) In this survey, it has been reported that almost 1.9 million people 
were current cocaine users. Psychostimulants promote dopamine pathways by signaling in 
the nucleus accumbens, the reward producing area, which calls upon euphoria feelings that 
eventuate the drug-taking and -seeking and leads to addiction. (Nestler, 2005) Furthermore,  
long-time cocaine exposure causes neuroinflammation which is another underlying reason 
for cocaine addiction. The consequences of physiological disorders because of cocaine use 
are—physical withdrawal, increasing use with time, and failure to participate in works at 
work, school, or home. 
Unfortunately, there is no current FDA-approved treatment for addiction to 
psychostimulant substances and finding any medicine to prevent addiction and relapse is 
preeminent for America as well as the rest of the world. 
Mycobacterium vaccae  
The aims of our collaborative research were in finding new medicine for drug 
treating addiction, relapse, and withdrawal. Our research was designed based on some 
unique neuropharmacological properties of M. vaccae which is a nonpathogenic 
environmental bacterium, belongs to the family of Mycobacteriaceae that is found in the 
soil. Multiple studies have proved that M. vaccae has positive effects on certain 
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neurological disorders such as post-traumatic stress. Immunization with heat-killed M. 
vaccae has immunoregulatory properties and can prevent stress-induced spontaneous 
colitis, over neuroinflammation, also it has both anxiolytic or fear-reducing effects. (Reber 
et al., 2016) It works by stimulating the neurons which contain serotonin signaling 
pathways and heightens the serotonin levels in the dorsal raphe nucleus to respond to stress 
and anxiety-like behavioral.  (Lowry et al., 2007)  
Based on  M. vaccine's pharmacological profile—it might have effects against 
cocaine addiction and relapse and we studied the effect of M. vaccae immunization on 
cocaine-induced CPP and stress-induced reinstatement of cocaine CPP. 
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Figure 140. (Bristol, 2007) Colonies of Mycobacterium vaccae which was Sauton's agar. 
(Bristol, 2007) This bacterium is usually found in soil, which is not harmful to human; was 
isolated in Uganda and that it showed immunization effect against leprosy. After that 
numerous studies indicated its medical value as a vaccine for different diseases. (Wallis & 
Johnson, 2009) 
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Methodology 
Animal and drug. Drug and Animal: C57 BL/6 male mice were used for this 
investigation and as drugs cocaine 30 mg/kg, heat-killed M. vaccae (0.1 mg, s.c.) or vehicle 
(borate-buffered saline) were administrated according to the research plan. M. vaccae (3 x 
0.1 mg, s.c.), regimen is reliable in both mice and rat models for neurological and 
behavioral studies.  
General cocaine CPP procedure. The CPP training for cocaine is almost the same 
as mentioned in the early in methodology session. But prior to providing cocaine CPP 
training, two groups of animals—one group was preimmunized M. vaccae (3 x 0.1 mg, 
s.c.) and another group was preimmunized with vehicle (s.c. borate-buffered saline). To 
confirm the proper preimmunization, each animal had an individual animal ID to identify 
the animal which received the vehicle and M. vaccae. The immunization was occurred 
inside the CMRSU vivarium three times over 14 days with even time intervals.   
When immunization was done then the cocaine CPP procedure was started which 
also followed an unbiased procedure where any animal showing >70% initial preference 
for any compartment was excluded before further training and the duration of training or 
test session was also for 30 minutes. The qualified animals were then trained over 10 days, 
either after getting cocaine or saline vehicle injections (i.p.). After 10 days of consecutive 
training, animals were tested for CPP expression to know the preference score for cocaine-
paired side and whether preimmunization did affect the cocaine-induced CPP or not.  
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Figure 151. The schematic presentation of M. Vaccace preimmunization test for cocaine 
CPP methodology.  The animals arrive in vivarium of Cooper Medical School of Rowan 
University (CMSRU) where theyhave been kept for five days. Prior to inject (s.c.) M. 
vaccae (3 x 0.1 mg) or vehicle (borate-buffered saline) three times in 14 days, they were 
handled  for two days to make them comfortable with researchers. After immunization,  
they are being placed in CPP chambers for initial bias test for three sessions and after that  
ten days (ten sessions) CPP training. After successfully completing training, they have been 
tested for CPP expression and finally stress-induced (forced swim ) reinstatement test 
followed by CPP extinction. 
 
  
67 
 
Then after two sessions of extinction, we tested the for stress-induced cocaine 
reinstatement. We used the forced swim method to induce stress prior to placement in CPP 
chamber which has been detailed earlier. 
Statistical Analysis. 
During CPP expression 
𝑃𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑆𝑐𝑜𝑟𝑒
= time spent in drug side on test  day 
− time spent in drug side before training  
During reinstatement test 
Preference Score = time spent on drug side − time spent in the vehicle side 
Result: M. vaccae attenuated stress-induced cocaine CPP 
Our investigation found that the animals which were preimmunized with heat-killed 
M. vaccae did not affect the 30 mg/kg cocaine-induced CPP immediately after training and 
it was near same as vehicle immunized animals. But the in stress-induced reinstatement, 
there was significant changed between the vehicle and M. vaccae group. Heat-killed M. 
vaccae preimmunized animals showed almost no preference for the cocaine-paired side but 
the animals which preimmunized with vehicle scored higher.This of result  indicated  that 
though M. vaccae did not affect the cocaine-induced CPP after training it effectively 
attenuated the stress-induced cocaine CPP.  
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Discussion 
Relapse is the most unavoidable event during the addiction treatment one of the 
principal reasons for relapse is stress. (Sinha, Garcia, Paliwal, Kreek, & Rounsaville, 2006) 
Scientists often test this human stress-induced relapse in animals through stress-induced 
reinstatement. (Y. Shaham, U. Shalev, L. Lu, H. de Wit, & J. Stewart, 2003) Like any other 
addiction treatment, cocaine relapse is also challenging to fight. Heat-killed M. vaccae 
preimmunization clearly reduced the effects of stress-induced relapse for cocaine addictive 
animals ( Figure 22). Since  M. vaccae also has anxiolytic effects, and our investigation 
proved the anti-relapse effects, it might be beneficial for the patients who are in treatment 
for cocaine addiction.  
Conclusion 
Finding a new medicine for treating cocaine addiction is intriguing but at the same 
time one of demanding job. Our current umbrella project for finding a medicine for 
neuropsychiatric disorders including addiction, abuse and dependence is continuing 
investigation with new idea and with new collaborations. Investigations on properties of 
M. vaccae are happeining now with some specific set of goals which will soon decode 
more addiction neuropharamclogical properties of this nonpathogen bacterium along with 
the postive effects on stress-induced reinstatement for cocaine.  
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Figure 162. M. vaccae preimmunization effects on cocaine CPP. Two groups of animals 
(n=8-12 for each group) were used for this test. Animals were pre-immunized with vehicle 
or heat-killed M. vaccae three times in seven days intervals and then were palced for three 
initial preference test , 10 sessions of CPP training with cocaine 30 mg/kg. After training 
animals were tested for CPP expression and then,  stress-induced (forced-swim) 
reinstatement followed by extinctions. Animals nevertheless   immunization with M. 
vaccae or vehicle, did not alter cocaine 30 mg/kg induced CPP acquisition wherein both 
vehicle and heat-killed M. vaccae (3 x 0.1 mg, s.c.)  showed the considerable score for the 
cocaine-paired side. But after the extinction sessions,  stress-induced (forced-swim) 
reinstatement was attenuated by heat-killed M. vaccae preimmunization. Data presented as 
means ± SEM. *p < 0.05, repeated-measures 2-way ANOVA with Sidak's multiple 
comparisons test. 
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